Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS

Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS

Publication date: Sep 22, 2025

Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID. Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia. Research has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte/T cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection. The purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo

Concepts Keywords
Immunocompromised Long COVID
Influenza
Professional
Sleepiness
Weeks

Semantics

Type Source Name
disease IDO protein
disease MESH Long COVID
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH Postural Orthostatic Tachycardia Syndrome
disease MESH syncope
disease MESH tachycardia
disease IDO production
disease IDO cell
disease IDO immune response
disease MESH infection
disease MESH orthostatic hypotension
disease MESH influenza
disease MESH sore throat
disease MESH dyspnea
disease MESH anorexia
disease IDO history
disease IDO nucleic acid
disease MESH immunocompromised patients
disease MESH cardiovascular disease
disease MESH atrioventricular block
disease MESH myocardial infarction
disease MESH heart failure
disease MESH stroke
disease MESH transient ischemic attack
disease MESH hypertension
disease MESH type 2 diabetes mellitus

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *